Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)
← catalyst calendarNCT06569602 · readout in 1,503 d
Sponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
500estimated
Sites
2
Countries
Germany, Switzerland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-01 | actual | When the study began enrolling |
| Primary completion | 2030-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-10-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Tricuspid Valve Regurgitation
- Heart Valve Diseases
- Cardiovascular Diseases
Intervention
- Device: Transcatheter Tricuspid Valve Replacement — also filed as Edwards EVOQUE Tricuspid Valve Replacement System
Primary outcomes
what the primary-completion date above is the date OFTricuspid regurgitation grade
measured Up to 7 days, 30 days, and 1 year
Number of patients with major adverse events (MAE rates)
measured 30 days
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed